Literature DB >> 18483393

Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor.

Frank Breitenbuecher1, Susanne Schnittger, Rebekka Grundler, Boyka Markova, Birgit Carius, Alexandra Brecht, Justus Duyster, Torsten Haferlach, Christoph Huber, Thomas Fischer.   

Abstract

In acute myeloid leukemia (AML), internal tandem duplications (ITDs) of the juxtamembrane (JM) of FLT3 have been shown to play a crucial role in driving proliferation and survival of the leukemic clone. Here, we report the identification of FLT3_ITD mutations located in non-JM domains of the FLT3-receptor. This novel type of FLT3_ITD mutation was found in 216 of 753 (28.7%) of unselected FLT3_ITD-positive AML cases. An FLT3 receptor harbouring a prototypic non-JM ITD (FLT3_ITD627E) mediated constitutive phosphorylation of FLT3 and of STAT5, suggesting that non-JM ITDs confer constitutive activation of the receptor. FLT3_ITD627E induced transformation of hematopoietic 32D cells and led to a lethal myeloproliferative disease in a syngeneic mouse model. Our results indicate that a significant proportion of activating FLT3_ITD mutations is not confined to the JM domain of FLT3. Further studies are warranted to define the biologic and clinical characteristics of non-JM ITDs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18483393     DOI: 10.1182/blood-2007-11-125476

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  55 in total

1.  Mutations in the transmembrane and juxtamembrane domains enhance IL27R transforming activity.

Authors:  Que T Lambert; Anuradha Pradhan; J Devon Roll; Gary W Reuther
Journal:  Biochem J       Date:  2011-08-15       Impact factor: 3.857

Review 2.  FLT3 inhibitors in AML: are we there yet?

Authors:  Akshay Sudhindra; Catherine Choy Smith
Journal:  Curr Hematol Malig Rep       Date:  2014-06       Impact factor: 3.952

Review 3.  FLT3 inhibitors in the treatment of acute myeloid leukemia: the start of an era?

Authors:  Naveen Pemmaraju; Hagop Kantarjian; Farhad Ravandi; Jorge Cortes
Journal:  Cancer       Date:  2011-02-11       Impact factor: 6.860

Review 4.  Allogeneic stem cell transplantation in first complete remission.

Authors:  Betul Oran; Daniel J Weisdorf
Journal:  Curr Opin Hematol       Date:  2011-11       Impact factor: 3.284

5.  Prognostic impact of white blood cell count in intermediate risk acute myeloid leukemia: relevance of mutated NPM1 and FLT3-ITD.

Authors:  Hendrik J M de Jonge; Peter J M Valk; Eveline S J M de Bont; Jan Jacob Schuringa; Gert Ossenkoppele; Edo Vellenga; Gerwin Huls
Journal:  Haematologica       Date:  2011-05-23       Impact factor: 9.941

6.  Impact of FLT3-ITD length on prognosis of acute myeloid leukemia.

Authors:  Song-Bai Liu; Hao-Jie Dong; Xie-Bing Bao; Qiao-Cheng Qiu; Hong-Zhi Li; Hong-Jie Shen; Zi-Xuan Ding; Chao Wang; Xiao-Ling Chu; Jing-Qiu Yu; Tao Tao; Zheng Li; Xiao-Wen Tang; Su-Ning Chen; De-Pei Wu; Ling Li; Sheng-Li Xue
Journal:  Haematologica       Date:  2018-08-03       Impact factor: 9.941

Review 7.  The Future of Targeting FLT3 Activation in AML.

Authors:  Mark B Leick; Mark J Levis
Journal:  Curr Hematol Malig Rep       Date:  2017-06       Impact factor: 3.952

8.  Impact of FLT3-ITD location on sensitivity to TKI-therapy in vitro and in vivo.

Authors:  T Fischer; F H Heidel; P Arreba-Tutusaus; T S Mack; L Bullinger; T M Schnöder; A Polanetzki; S Weinert; A Ballaschk; Z Wang; A J Deshpande; S A Armstrong; K Döhner
Journal:  Leukemia       Date:  2015-10-21       Impact factor: 11.528

Review 9.  The role of molecular tests in acute myelogenous leukemia treatment decisions.

Authors:  Gabriela Motyckova; Richard M Stone
Journal:  Curr Hematol Malig Rep       Date:  2010-04       Impact factor: 3.952

Review 10.  Potential role of sorafenib in the treatment of acute myeloid leukemia.

Authors:  Shahram Mori; Jorge Cortes; Hagop Kantarjian; Weiguo Zhang; Michael Andreef; Farhad Ravandi
Journal:  Leuk Lymphoma       Date:  2008-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.